Overview Dividends

(FDMT) 4D Molecular Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US35104E1001

Ophthalmology, Cystic-Fibrosis, Geographic-Atrophy, Alpha-1-Antitrypsin-Deficiency, Fabry-Disease

FDMT EPS (Earnings per Share)

EPS Growth (3Y CAGR): 77.61%
EPS Trend (3Y Correlation): 21.2%

FDMT Revenue

Revenue Growth (3Y CAGR): -72.06%
Revenue Trend (3Y Correlation): -34.1%

Description: FDMT 4D Molecular Therapeutics October 29, 2025

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is a late-stage biotech focused on engineering adeno-associated virus (AAV) vectors through its proprietary Therapeutic Vector Evolution platform, operating labs in the Netherlands and the United States.

The company’s lead candidate, 4D-150, aims to treat retinal vascular diseases-including wet age-related macular degeneration (wAMD) and diabetic macular edema-by delivering a multi-year, intravitreal anti-VEGF expression system. The global anti-VEGF market is valued at roughly $10 billion and is projected to grow at a 6-7 % CAGR, making sustained-release gene-based approaches a potentially disruptive cost-controlling alternative.

Beyond 4D-150, the pipeline includes 4D-710 (early-stage cystic fibrosis), 4D-175 (preclinical geographic atrophy), 4D-725 (preclinical α1-antitrypsin deficiency lung disease), and 4D-310 (Phase 1 Fabry disease). Collectively, these programs address rare-disease indications that together represent a $30 billion addressable market for gene-therapy modalities.

Strategic collaborations with Astellas Gene Therapies, Arbor Biotechnologies, and uniQure provide both development expertise and non-dilutive funding; the company reported a cash runway of approximately $150 million as of its latest 10-Q, supporting runway through at least 2026 under current burn rates.

For a deeper, data-driven look at FDMT’s valuation dynamics and scenario analysis, you might find the free tools on ValueRay useful for extending your own research.

FDMT Stock Overview

Market Cap in USD	537m
Sub-Industry	Biotechnology
IPO / Inception	2020-12-11

FDMT Stock Ratings

Growth Rating	-0.11%
Fundamental	28.5%
Dividend Rating	-
Return 12m vs S&P 500	13.9%
Analyst Rating	4.0 of 5

FDMT Dividends

Currently no dividends paid

FDMT Growth Ratios

Growth Correlation 3m	89.8%
Growth Correlation 12m	19.9%
Growth Correlation 5y	-65.2%
CAGR 5y	3.96%
CAGR/Max DD 3y (Calmar Ratio)	0.04
CAGR/Mean DD 3y (Pain Ratio)	0.08
Sharpe Ratio 12m	-0.96
Alpha	-14.06
Beta	2.921
Volatility	73.07%
Current Volume	1322.2k
Average Volume 20d	745.6k
Stop Loss	10.1 (-7.5%)
Signal	0.07

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-196.1m TTM) > 0 and > 6% of Revenue (6% = 1980 TTM)

FCFTA -0.35 (>2.0%) and ΔFCFTA -21.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 814.0k% (prev 2637 %; Δ 811.3kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.35 (>3.0%) and CFO -166.4m > Net Income -196.1m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (55.9m) change vs 12m ago 1.17% (target <= -2.0% for YES)

Gross Margin -16.2k% (prev 56.23%; Δ -16.2kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.01% (prev 3.26%; Δ -3.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -8.52 (EBITDA TTM -221.8m / Interest Expense TTM -26.1m) >= 6 (WARN >= 3)

Altman Z'' -17.19

(A) 0.57 = (Total Current Assets 303.3m - Total Current Liabilities 34.7m) / Total Assets 473.6m

(B) -1.43 = Retained Earnings (Balance) -678.8m / Total Assets 473.6m

warn (B) unusual magnitude: -1.43 — check mapping/units

(D) -12.86 = Book Value of Equity -678.5m / Total Liabilities 52.7m

Total Rating: -17.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 28.46

1. Piotroski 0.0pt = -5.0

2. FCF Yield -62.29% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.05 = 2.50

5. Debt/Ebitda 0.24 = 2.45

6. ROIC - WACC (= -52.22)% = -12.50

7. RoE -40.15% = -2.50

8. Rev. Trend -34.11% = -2.56

9. EPS Trend 21.23% = 1.06

What is the price of FDMT shares?

As of November 08, 2025, the stock is trading at USD 10.92 with a total of 1,322,237 shares traded.
Over the past week, the price has changed by -3.53%, over one month by +30.00%, over three months by +90.58% and over the past year by +30.78%.

Is 4D Molecular Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, 4D Molecular Therapeutics (NASDAQ:FDMT) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 28.46 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FDMT is around 10.27 USD . This means that FDMT is currently overvalued and has a potential downside of -5.95%.

Is FDMT a buy, sell or hold?

4D Molecular Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy FDMT.

Strong Buy: 5
Buy: 4
Hold: 2
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the FDMT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	32.9	201.2%
Analysts Target Price	32.9	201.2%
ValueRay Target Price	12.3	12.2%

FDMT Fundamental Data Overview November 04, 2025

Market Cap USD = 537.1m (537.1m USD * 1.0 USD.USD)
P/S = 16275.104
P/B = 0.962
Beta = 2.921
Revenue TTM = 33.0k USD
EBIT TTM = -222.2m USD
EBITDA TTM = -221.8m USD
Long Term Debt = 23.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.72m USD (from shortTermDebt, last quarter)
Debt = 23.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -54.1m USD (from netDebt column, last quarter)
Enterprise Value = 266.9m USD (537.1m + Debt 23.1m - CCE 293.2m)
Interest Coverage Ratio = -8.52 (Ebit TTM -222.2m / Interest Expense TTM -26.1m)
FCF Yield = -62.29% (FCF TTM -166.3m / Enterprise Value 266.9m)
FCF Margin = -503.9k% (FCF TTM -166.3m / Revenue TTM 33.0k)
Net Margin = -594.4k% (Net Income TTM -196.1m / Revenue TTM 33.0k)
Gross Margin = -9999 % ((Revenue TTM 33.0k - Cost of Revenue TTM 5.38m) / Revenue TTM)
Gross Margin QoQ = -9999 % (prev 100.0%)
Tobins Q-Ratio = 0.56 (Enterprise Value 266.9m / Total Assets 473.6m)
Interest Expense / Debt = 6.12% (Interest Expense 1.41m / Debt 23.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -175.5m (EBIT -222.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.75 (Total Current Assets 303.3m / Total Current Liabilities 34.7m)
Debt / Equity = 0.05 (Debt 23.1m / totalStockholderEquity, last quarter 420.9m)
Debt / EBITDA = 0.24 (negative EBITDA) (Net Debt -54.1m / EBITDA -221.8m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -54.1m / FCF TTM -166.3m)
Total Stockholder Equity = 488.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.41% (Net Income -196.1m / Total Assets 473.6m)
RoE = -40.15% (Net Income TTM -196.1m / Total Stockholder Equity 488.5m)
RoCE = -43.43% (EBIT -222.2m / Capital Employed (Equity 488.5m + L.T.Debt 23.1m))
RoIC = -35.93% (negative operating profit) (NOPAT -175.5m / Invested Capital 488.5m)
WACC = 16.29% (E(537.1m)/V(560.2m) * Re(16.78%) + D(23.1m)/V(560.2m) * Rd(6.12%) * (1-Tc(0.21)))
Discount Rate = 16.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.55%
Fair Price DCF = unknown (Cash Flow -166.3m)
EPS Correlation: 21.23 | EPS CAGR: 77.61% | SUE: 4.0 | # QB: 1
Revenue Correlation: -34.11 | Revenue CAGR: -72.06% | SUE: -0.13 | # QB: 0

Additional Sources for FDMT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle